Identification of pathway-based prognostic gene signatures in patients with multiple myeloma.
Zamani-Ahmadmahmudi M et al. Transl Res. 2017 May 9. pii: S1931-5244(17)30041-5. doi: 10.1016/j.trsl.2017.05.001. [Epub ahead of print].

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.
Łuczak M, Kubicki T et al. Pol Arch Intern Med. 2017 May 25. doi: 10.20452/pamw.4032. [Epub ahead of print].

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
Lahuerta JJ et al. J Clin Oncol. 2017 May 12:JCO2016692517. doi: 10.1200/JCO.2016.69.2517. [Epub ahead of print].

Neuro-Myelomatosis of the Brachial Plexus – An Unusual Site of Disease Visualized by FDG-PET/CT: A Case Report.
Fukunaga H et al. Am J Case Rep. 2017 May 1;18:478-481.

Identification of precision treatment strategies for relapsed/ refractory multiple myeloma by functional drug sensitivity testing.
Majumder MM et al. Oncotarget. 2017 May 5. doi: 10.18632/oncotarget.17630. [Epub ahead of print].

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.
Oberle A et al. Haematologica. 2017 May 18. pii: haematol.2017.169235. doi: 10.3324/haematol.2017.169235. [Epub ahead of print].

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.
Schinke C et al. Haematologica. 2017 May 18. pii: haematol.2017.165217. doi: 10.3324/haematol.2017.165217. [Epub ahead of print].

Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib.
Iriyama N et al. Oncol Lett. 2017 May;13(5):3803-3808. doi: 10.3892/ol.2017.5920.

Vascular endothelial growth factor receptor 3 is a novel marker differing CD138-positive and CD138-negative multiple myeloma cells.
Kostjukova MN et al. Br J Haematol. 2017 May 16. doi: 10.1111/bjh.14706. [Epub ahead of print].

Identification and expression of MMSA-8, and its clinical significance in multiple myeloma.
He R et al. Oncol Rep. 2017 Jun;37(6):3235-3243. doi: 10.3892/or.2017.5609. Epub 2017 Apr 28.

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
Kis O et al. Nat Commun. 2017 May 11;8:15086. doi: 10.1038/ncomms15086.

Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Willrich MAV et al. Clin Biochem. 2017 May 4. pii: S0009-9120(16)30742-1. doi: 10.1016/j.clinbiochem.2017.05.001. [Epub ahead of print].

Serial measurements of circulating plasma cells before and after induction therapy has an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation.
Chakraborty R et al. Haematologica. 2017 May 4. pii: haematol.2017.166629. doi: 10.3324/haematol.2017.166629. [Epub ahead of print].

A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System.
Jung SH et al. Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14701. [Epub ahead of print].

[11 C]Methionine emerges as a new biomarker for tracking active myeloma lesions.
Lapa C et al. Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14696. [Epub ahead of print].

Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases.
Qian J et al.Hematology. 2017 May 2:1-5. doi: 10.1080/10245332.2017.1309493. [Epub ahead of print].